Clavanin A Improves Outcome of Complications from Different Bacterial Infections

• DOI: 10.1128/aac.03732-14
• Publication Date: 2014-12-30T08:32:47Z
• Authors: Osmar N. Silva; Isabel C. M. Fens...; Elaine A. Rodrigues; Hortência H. S. H...; Natasha R. F. Novaes; Junia P. A. Cunha; Taia M. B. Rezende; Kelly G. Magalhães; Susana E. Moreno; Márcio S. Jerônimo; Anamélia L. Bocca; Octavio L. Franco
• Keywords: Mice, Inbred C57BL; 0301 basic medicine; Mice; Staphylococcus aureus; 03 medical and health sciences; Anti-Infective Agents; Escherichia coli; Animals; Blood Proteins; Staphylococcal Infections; Peptides; Escherichia coli Infections; 3. Good health

The rapid increase in the incidence of multidrug-resistant infections today has led to enormous interest antimicrobial peptides (AMPs) as suitable compounds for developing unusual antibiotics. In this study, clavanin A, an peptide previously isolated from marine tunicate Styela clava, was selected a purposeful molecule that could be used controlling infection and further synthesized. Clavanin A vitro evaluated against Staphylococcus aureus Escherichia coli well toward L929 mouse fibroblasts skin primary cells (SPCs). Moreover, challenged here vivo wound sepsis model, immune response also analyzed. Despite displaying clear activity Gram-positive -negative bacteria, showed no cytotoxic activities mammalian cells, acute toxicity tests, adverse reaction observed at any concentrations. significantly reduced S. CFU experimental model. This mortality mice infected with E. by 80% compared control animals (treated phosphate-buffered saline [PBS]): these data suggest prevents start thereby reduces mortality. These is AMP improve development novel peptide-based strategies treatment infections.